SAGE-718 for Mild Cognitive Impairment

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Mild Cognitive Impairment+2 MoreSAGE-718 - Drug
Eligibility
50 - 80
All Sexes
What conditions do you have?
Select

Study Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.

Eligible Conditions
  • Mild Cognitive Impairment
  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: From the inform consent signing up to end of the study (Up to approximately Day 116)

Baseline to Day 84
Change from Baseline in the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test
Day 116
Number of Participants Who Withdraw Due to Adverse Events (AEs)
Percentage of Participants With At least One or More Treatment-emergent Adverse Events (TEAEs) and by Severity

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

SAGE-718
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

150 Total Participants · 2 Treatment Groups

Primary Treatment: SAGE-718 · Has Placebo Group · Phase 2

SAGE-718
Drug
Experimental Group · 1 Intervention: SAGE-718 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: SAGE-718-matching Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SAGE-718
2020
Completed Phase 2
~140

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from the inform consent signing up to end of the study (up to approximately day 116)

Who is running the clinical trial?

Sage TherapeuticsLead Sponsor
49 Previous Clinical Trials
9,105 Total Patients Enrolled

Eligibility Criteria

Age 50 - 80 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a clinical dementia rating (CDR) score of 0.5 to 1.